natgillin/translations-raw huggingface dataset:
The mouse cell of claim 9 or 10, wherein the endogenous λ light chain immunoglobulin locus comprises the endogenous mouse enhancer 2.4 or the endogenous mouse 3' enhancer. 
Mišja stanica prema zahtjevu 6, naznačena time, što endogeni lokus imunoglobulina lakog lanca A sadrži endogeni mišji pojačivač 2.4 ili endogeni mišji 3' pojačivač.
The rodent of Clause 17, wherein the rodent is a mouse. The mouse of Clause 18, wherein the first nucleotide sequence encodes a chimeric human/mouse MHC I polypeptide, and wherein a mouse portion of the chimeric MHC I polypeptide is derived from H-2K, H-2D, or H-2L. 
Glodavac prema zahtjevu 8, naznačen time, da glodavac je miš, i time, da prva nukleotidna sekvenca kodira kimerni ljudski/mišji MHC-I-polipeptid, te je pritom mišji dio kimernog MHC-I-polipeptida izveden iz H-2K, H- 2D ili H-2L.
The system according to at least one of the preceding claims, wherein a plurality of armouring elements (21, 22, 23, 24, 25) comprises at least one transparent or translucent slab (210, 220, 230, 240, 250) made of armoured material, defining respective windows of the cab. 
Teleskopski manipulator prema najmanje jednom od prethodnih patentnih zahtjeva, pri čemu više oklopnih elemenata (21, 22, 23, 24, 25) sadrži najmanje jednu transparentnu ili translucentnu tablu načinjenu od oklopnog materijala, definirajući odgovarajuće prozore kabine.
adding a solution of BF3·Et2O in anhydrous dichloromethane dropwise with stirring over 1 hour to a solution of (+)-cannabidiol in anhydrous dichloromethane at -5°C, stirring the resultant mixture for 1.5 hours at -5°C, adding the mixture to a mixture of ice and 7% NaHCO3, and isolating from the organic phase the crude trans-(+)-A9-tetrahydrocannabinol used in step (2). 
dodavanje otopine BF3·Et2O u bezvodnom diklorometanu kap po kap uz miješanje tijekom 1 sata u otopinu (+)-kanabidiola u bezvodnom diklorometanu na -5°C, miješanje nastale smjese tijekom 1.5 sata na -5°C, dodavanje smjese u smjesu leda i 7% NaHCO3, te izoliranje iz organske faze sirovog trans-(+)-A9-tertahidrokanabinola koji je korišten u koraku (2).
CASTOR WHEEL DEVICE FOR FURNITURE AND THE LIKE, according to claim 2, characterised in that the skid (20) is arranged after the pivoting axis (3), with reference to the rotational direction of the wheel (1) corresponding to the advancement of the device to which the wheel is fastened. 
Naprava kotačića za namještaj 1 slično, prema patentnom zahtjevu 2, naznačena time što je klizač (20) postavljen pred os zakretanja (3), s obzirom na smjer rotacije kotača (1), što odgovara napretku naprave na koji je kotač pričvršćen.
In some other embodiments, a formulation of the invention is in the form of a gel, lotion, cream, spray, aerosol, ointment, emulsion, suspension, liposomal system, lacquer, patch, bandage, buccal tablet, wafer, sublingual tablet, suppository, vaginal dosage form or occlusive dressing. In a particular embodiment, the formulation is a gel. 
Formulacija prema bilo kojem od zahtjeva 1 do 12, naznačena time, da je navedena formulacija u obliku gela, losiona, kreme, spreja, aerosola, masti, emulzije, suspenzije, liposomnog sustava, laka, flastera, zavoja, bukalne tablete, sublingvalne tablete, čepića, vaginalnog doznog oblika ili okluzivnog zavoja, te poželjno u obliku gela.
The housing element according to any one of claims 12 and 13, wherein at least one of the two sheet materials is a plastic material, in particular polypropylene, or polyester, or polyethylene, or polylactide, or polyamide, or polystyrene, or polyvinyl chloride, or else a combination of these, and, possibly, is treated with a process of metallization or lacquering. 
Element kućišta u skladu s bilo kojim od patentnih zahtjeva 12 1 13, naznačen time što je najmanje jedan od dva materijala za foliju plastični materijal, osobito polipropilen, ili poliester, ili polietilen, ili polilaktid, ili poliamid, ili polistiren, ili polivinil-klorid, ili pak kombinacija navedenih, uz moguću obradu postupkom metaliziranja ili lakiranja.
The pair of DNA molecule of claim 2, wherein said first DNA molecule hybridizes specifically to SEQ ID NO:5 from about nucleotide position 2060 through about nucleotide position 12,208, and wherein said second DNA molecule hybridizes specifically to the reverse complement sequence of SEQ ID NO:3 from about nucleotide position 1 through about position 2050. 
(ii) se prva navedena DNA molekula specifično hibridizira sa SEQ ID NO: 5 na nukleotidnoj poziciji od oko 2060 do nukleotidne pozicije 12,208, 1 pri čemu spomenuta druga DNA molekula specifično hibridizira obrnuti redoslijed sekvence koja odgovara SEQ ID NO: 3 pozicije nukleotida od oko 1 do oko pozicije 2050.
is selected from the group consisting of H and alkyl; 
R* je izabran iz skupine koja se sastoji od H i alkila;
A packaging according to any of the preceding claims, wherein a back part of the inner part composes the hinging part between the two sides, the back part being covered by a metal part/layer. 
Pakiranje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time, što stražnji dio unutarnjeg dijela tvori zglobni dio između dvije strane, pri čemu je stražnji dio prekriven metalnim dijelom/slojem.
The variation in basal fluorescence was less than 10%. 
Varijacija u bazalnoj fluorescenciji bila je manja od 10%.
Finally, said veneer having a thickness between 0.1 and 0.8 mm and a humidity content of more than the fiber saturation point of the wood is overlaid and glued onto a substrate. 
Na kraju, navedeni furnir koji ima debljinu između 0.1 i 0.8 mm i sadržaj vlage od više nego što je točka zasićenja vlakana drva, polaže se i lijepi na podlogu.
Freeze-drying the powder to provide said instant coffee powder. 
sušenja smrzavanjem praha kako bi se dobilo navedenu instant kavu u prahu.
Item 7. The compound according to Item 1 or a salt thereof, which is selected from the group consisting of: 
Spoj u skladu s patentnim zahtjevom 1, ili njegove soli, naznačen time da se bira iz skupine koju čine
In a particular embodiment of the first aspect of the present invention, the above-mentioned compound of formula (5): is prepared by the following step A4: wherein a compound of formula (4): 
NH, ostavljen da reagira sa sredstvom za žarenje, čime se dobiva spoj s formulom (6); navedeni spoj s formulom (5): se priprema u sljedećem koraku A4: pri čemu je spoj s formulom (4):
The reception method according to claim 1, wherein the search space only includes candidates for the localized allocation or only includes candidates for the distributed allocation. 
Metoda prijema sukladno jednom od zahtjeva 1 ili 2, naznačena time da je prostor pretraživanja konfiguriran u podatkovnom predjelu podokvira silazne veze.
(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt; and 
Farmaceutski pripravak naznačen time da sadrži kombinaciju (1S)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-D-glucitol ili njegova farmaceutski prihvatljiva sol ili hidrat spoja ili soli; te
The platform according to claim 18, wherein said one or more inducers are selected from the group consisting of 4-aminophenyl-B-D-galactopyranoside, isopropyl-B-D-thiogalactopyranoside, 1-O-Methyl-B-D-galactopyranoside, Methyl-B-D-thiogalactopyranoside, 1-o-Methyl-a-D-galactopyranoside, Isopropyl-B-D-thioglucopyranoside, 1-O-methyl-B-D-glucopyranoside, Isopropyl-B-D-thioglucouronic acid, 1-O-Methyl-B-D-glucouronic acid, sodium salt. 
Platforma prema bilo kojem od zahtjeva 1 do 9, gdje se taj jedan ili više induktora izabiru iz grupe koja obuhvaća 4- aminofenil-fB-D-galaktopiranozid, izopropil -f-D-tiogalaktopiranozid, 1-O-Metil-B-D-galaktopiranozid, Metil-f3-D- tiogalaktopiranozid,
Said conductor 110 is reached, through a limiting resistor 71, by the collector current of transistor 70, to which a Miller capacitor 72 is applied. 
Na spomenuti vodič 110 dolazi preko limiterskog otpornika 71, struja kolektora tranzistora 70, na koji je spojen Millerov kapacitet 72.
wherein R4 and R5, taken together with the intervening oxygen and boron atoms, form an optionally substituted 5-membered ring; or 
(c) gdje R' i R', uzeti zajedno sa atomima kisika i bora koji se nalaze između, formiraju izborno supstituirani 5-člani prsten; ili
Concentrator according to anyone of claim 19 to 24, further adapted to perform the operation of determining whether a remote meter (RM) is enabled to perform the operation of transmitting an amount (L) of consumption related data (MV1, MV2... 
Sabirnik prema bilo kojem od patentnih zahtjeva 19 do 24, nadalje prilagođen za provođenje operacija utvrđivanja je li daljinskom brojaču (RM) omogućeno provođenje operacija prijenosa količine (L) periodički izmjerenih i pohranjenih podataka vezanih uz potrošnju (MV1, MV2...
The construct for the use of claims 1 to 9, wherein the CD19xCD3 bispecific single chain antibody construct is to be administered in a daily dose of 15µg, 30µg, 60µg or 90µg per square meter patient body surface area. 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što 5 µg/m2 površine pacijentovog tijela treba primijeniti prvog odnosno prvih dana perioda infuzije, za čim slijedi primjena 15 µg/m2 površine pacijentovog tijela kao dnevna doza kroz preostali period.
frequency transform means for transforming the low frequency component obtained by the core decoding means into a frequency domain; high frequency generating means for generating a high frequency component by copying the low frequency component transformed into the frequency domain by the frequency transform means from a low frequency band to a high frequency band; 
pretvarača frekvencije za pretvorbu niskofrekventne komponente dobivene iz osnovnog dekodera u frekventno područje; visokofrekventnog generatora za generiranje visokofrekventne komponente kopiranjem niskofrekventne komponente koju pretvarač frekvencije pretvara u frekventno područje iz niskofrekventnog pojasa u visokofrekventni pojas;
wherein the guide sleeve has a multiangular outer contour located along at least a portion of its outer circumference; and 
provodni rukav (80) ima višekutni vanjski obris (82) smješten barem na dijelu vanjskog kruga (81),
A conditional replication defective cytomegalovirus (CMV) comprising: 
Citomegalovirus (CMVY) s uvjetno defektnom replikacijom koji sadrži:
The method according to any one of the preceding items, wherein the composition is contacted with SiO2 at a final concentration of at least 1 g SiO2/g protein. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time, da se sastav stavlja u doticaj sa SiO, u konačnoj koncentraciji kako slijedi: (1) najmanje 1 g SiO,/g proteina;
A bispecific antibody specifically binding to human vascular endothelial growth factor (VEGF) and human angiopoietin-2 (ANG-2) comprising a first antigen-binding site that specifically binds to human VEGF and a second antigen-binding site that specifically binds to human ANG-2, wherein 
Bispecifično protutijelo koje se specifično veže na humani vaskularni endotelijalni faktor rasta (VEGF) i humani angiopoietin-2 (ANG-2), naznačeno time, da obuhvaća prvo mjesto vezivanja antigena, koje se specifično veže na humani VEGF i drugo mjesto vezivanja antigena, koje se specifično veže na humani ANG-2, pri čemu
the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide hybridizing under conditions of high stringency to the complement of SEQ ID NO: 1; 
(iv) sekvencu amino kiseline od receptora vezanih G-proteina kodiranu s polinukleotidima koji su hibridizirani pod uvjetima visoke oskudice prema dodatku od SEQ ID NO: 1;
Among the most instable unsaturated compounds comprised in the composition obtained by the process of the invention, the natural and non-natural oils, of both animal and vegetable origin as well as the products of their chemical modification, like fish and seed oils (triglycerides), the fatty acids and salts thereof obtained by hydrolysis, the alkyl esters thereof obtained by synthesis or by transesterification, as well as any of the derivatives thereof, can be mentioned. 
Među najnestabilnijim nezasićenim spojevima sadržanim u pripravku dobivenom prema postupku iz izuma, mogu se spomenuti prirodna i ne-prirodna ulja, i životinjskog 1 biljnog porijekla, kao i produkti njihove kemijske modifikacije, kao npr., riblje i ulja iz sjemenki (trigliceridi), masne kiseline i njihove soli dobivene hidrolizom, njihovi alkil esteri dobiveni sintezom ili transesterifikacijom, kao i bilo koji njihovi derivati.
In one aspect, the invention features a pharmaceutical composition comprising Form I and a pharmaceutically acceptable carrier. 
22. Farmaceutska smjesa koja sadrži Oblik I iz zahtjeva 1, i farmaceutski prihvatljiv nosač.
Compound (II) may be provided in unit dose form, for example as described for Compound (I). 
Spoj (Il) gdje je Spoj (II) u obliku suhog praha kao pripravka.
The method according to claim 1, wherein the solid mineral alkaline is selected from the group consisting of magnesium oxide, zinc oxide, barium oxide, calcium oxide, calcium hydroxide, limestone, magnesite, calcite, dolomite, chalk, caustic soda, and mixtures thereof. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da je kruta mineralna lužina odabrana iz skupine koju čine magnezijev oksid, cinkov oksid, barijev oksid, kalcijev oksid, kalcijev hidroksid, vapnenac, magnezit, kalcit, dolomit, kreda, kaustična soda 1 bilo koja njihova smjesa.
A pesticidal mixture comprising as active ingredient a mixture of component (A) and component (B), wherein component (A) is a compound of formula (I) 
komponenta (B) je acetamiprid, pri čemu maseni odnos komponente (A) prema komponenti (B) iznosi 125:1 do 1:33.
A crystalline polymorph of 6-(Piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride having the formula wherein the polymorph exhibits in an X-ray powder diffractogram using CuKa1 radiation at least reflections within the two ranges selected from 
NH O xHcl () naznačen time da polimorf iskazuje u difraktogramu X-zraka na prahu korištenjem CuKa; zračenja refleksije barem unutar dva raspona koji su odabrani od
A kit of parts for providing a roof or wall covering, said kit comprises o A roofing or wall covering element (1) for laying in an overlapping manner with other roofing or wall covering elements, said roofing or wall covering element comprises 
Komplet dijelova za opremanje krova ili zidne obloge, naznačen time da komplet sadrži o krovni element ili element zidne obloge (1) za postavljanje na preklapajući način s drugim krovnim elementima ili elementima zidne obloge, te navedeni krovni elementi ili elementi zidne obloge sadrže
The subject invention also provides R(+)-N-propargyl-1-aminoindan characterized by a powder X-ray diffraction pattern having peaks at 8.5, 12.6, 16.1, 16.9, 20.3, 20.9, 25.4, 26.4, and 28.3 in degrees two theta ±0.2; or by a melting point of 38-41°C. 
Kristalni R(+)-N-propargil-1-aminoindan prema patentnom zahtjevu 1, naznačen time, da slika rendgenske difrakcije praha ima pikove na 8,5, 12,6, 16,1, 16,9, 20,3, 20,9, 25,4, 26,4 1 28,3 u stupnjevima dva-teta +0,2.
cyano, a C1-6 alkoxy optionally having 1 to 3 substituents selected from 
(1) fenil koji opcijski ima 1 do 3 supstituenta odabrana od sljedećih:
it has an increased Fc-mediated cellular cytotoxicity which is at least 2 times higher than the Fc-mediated cellular cytotoxicity of at least one antibody molecule composition from the same antibody molecule when expressed in the cell line CHOdhfr- [ATCC No. CRL-9096]. 
(c) ima povećanu staničnu citotoksičnost vezanu uz Fc, koja je najmanje 2 puta veća od stanične citotoksičnosti vezane uz Fc pripravka s najmanje jednom molekulom protutijela za istu molekulu protutijela kada se eksprimira u staničnoj liniji ATCC No.
ethylene/methyl acrylate, ethylene/ethyl acrylate, and ethylene/butyl acrylate copolymers containing 20 to 35 weight percent alkyl acrylate residues, based on the weight of the copolymer; 
kopolimera etilen/metil-akrilata, etilen/etil-akrilata i etilen/butil-akrilata koji sadrže 20 do 35 posto, težinski, alkil-akrilatnih ostataka, prema težini kopolimera;
The coding according to the invention is implemented in a coding software module MC_CO 1 of the coder CO 1, such as represented in FIG. 
Računalni program koji sadrži instrukcije za provođenje postupka kodiranja prema zahtjevu 1, naznačen time da se navedeni postupak kodiranja provodi na računalu.
The oral controlled release pharmaceutical composition as in claim for the use in the treatment of traveler's diarrhea, hepatic encephalopathy, infectious diarrhea, diverticular disease, an antibacterial prophylactic prior to colon surgery, irritable bowel syndrome, Crohn's disease, Clostridum difficile-associated diarrhea, small intestinal bacterial overgrowth, traveler's diarrhea prophylaxis, dysentery, pouchitis, peptic ulcer disease, surgical prophylaxis and gastric dyspepsia. 
Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 1 naznačen time da je za uporabu u liječenju putnih proljeva, hepatičke encefalopatije, zaraznih proljeva, divertikularne bolesti, za antibakterijsku profilaksu prije operacije debelog crijeva, za liječenje sindroma nadražljivih crijeva, Crohnove bolesti, proljeva uzrokovanog bakterijom Clostridium difficile, prekomjernog broja bakterija u tankom crijevu, za profilaksu putnog proljeva, za liječenje dizenterije, pouchitisa (upale kirurški oblikovane crijevne vrećice), za predoperativnu profilaksu i za liječenje želučane dispepsije.
The reaction was stirred at room temperature over night, then poured onto ice and neutralized with NaOH. 
Reakcija se ostavi miješati preko noći na sobnoj temperaturi, potom se prelije na led i neutralizira sa NaOH.
Purified water was used as the granulating solution to prepare granules by mixing with nebivolol hydrochloride adsorbed blend till the mass of required consistency was obtained. 
Rabljena je pročišćena voda kao otopina za granulaciju da bi se dobile granule miješanjem smjese s adsorbiranim nebivolol hidrokloridom dok nije dobivena masa tražene konzistencije.
Method according to any one of the preceding claims, characterized in that following the addition of said 2-((1-methylpropyl)amino)ethanol, the suspension conductivity change is not more than 70 µS/cm per pH unit, and preferably is not more than 50 µS/cm per pH unit. 
5. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time da nakon dodavanja navedenog 2- ((1-metilpropiljamino)etanola, promjena vodljivosti nije veća od 70 uS/em po jedinici pH, a poželjno nije veća od 50 uS/em po jedinici pH.
as well as their physiologically acceptable salts and tautomeric forms. Another embodiment of this invention is a compound of the formula I in which 
CHF2, OCHF2, OCHZE, O-fenil, fenil, NO2; kao i njihove fiziološki prihvatljive soli i tautomerni oblici.
BVI is a chalcogen of group VIA, or group 16 in the IUPAC nomenclature, 
B" je halkogen iz skupine VI, ili skupine 16 u IUPAC-ovoj nomenklaturi,
The method of item 32 wherein the subject is suffering from a disorder selected from Alzheimer's Disease and schizophrenia. 
Farmaceutski sastav iz patentnog zahtjeva 3 za uporabu u metodi poboljšanja kognicije kod subjekta koji pati od Alzheimerove bolesti.
Method for controlling power fluctuation ramps having energy storage systems in plants for intermittent energy generation 
POSTUPAK KONTROLE RAMPI FLUKTUIRANJA SNAGE SUSTAVIMA ZA POHRANU ENERGIJE KOD ELEKTRANA ZA INTERMITENTNO GENERIRANJE ENERGIJE
The crude product was purified with a flash chromatography on silica gel eluted with 50% ethyl acetate in hexane to yield compound 10b as a pale yellow solid (27 g, 44 mmol, 78%). 
Sirovi produkt pročisti se flash-kromatografijom na silikagelu, uz eluiranje 50 %-tnim etil-acetatom u heksanu kako bi se dobilo spoj 10b u obliku blijedožute krutine (27 g, 44 mmol, 78 %).
curing said coating layer, so as to fix the orientation of the said flake pigment particles; 
otvrdnjavanje navedenog premaznog sloja, tako da se fiksira usmjerenje navedenih čestica ljuskastog pigmenta (3);
The composition of claim 22, wherein the CD19 antigen binding domain of the CAR is encoded by a nucleic acid sequence comprising SEQ ID NO:14, the CD8a hinge domain of the CAR is encoded by a nucleic acid sequence comprising SEQ ID NO:15, the CD8a transmembrane domain of the CAR is encoded by a nucleic acid sequence comprising SEQ ID NO:16, and the 4-1BB costimulatory signaling region of the CAR is encoded by a nucleic acid sequence comprising SEQ ID NO:17. 
(v) anti-CD19 scFv je kodiran sekvencom SEQ ID NO: 14, signalni region 4-1BB je kodiran sekvencom SEQ ID NO: 17 i signalnu domenu CD3 zeta je kodiran sekvencom SEQ ID NO: 18; ili (v1) CAR je kodiran sekvencom nukleinske kiseline naznačenom u sekvenci SEQ ID NO:8.
In an alternate configuration, the container 101 may be enclosed with a base 202 having an agitating means 203 as shown in FIG. 2D . 
U drugoj konfiguraciji, posuda 101 može biti dana s postoljem 202 koje ima dijelove za miješanje 203 kako je prikazano na Slici 2D.
zirconia, may be included in the composite material, and a certain fraction of these filler particles may have particular physical properties, i.e. 
cirkonijev oksid, mogu biti obuhvaćena u kompzitnom materijalu, a neke frakcije tih čestica za punjenje mogu imati određena fiziklana svojstva, tj.
A compound or a stereoisomer, tautomer, pharmaceutically-acceptable salt, or solvate thereof, according to claim 1 or 2, for use in treating an inflammatory or autoimmune disease. 
Spoj ili stereoizomer, tautomer, farmaceutski-prihvatljiva sol, ili solvat tog spoja, u skladu sa patentnim zahtjevom
The compound according to claim 12, wherein the compound is 4′-ethyl- 3,4-dihydroxybiphenyl-2,6-dicarbonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, daje spoj 3,4-dihidroksi-3',4'-dimetilbi fenil-2,6- dikarbonitril.
The present invention provides an orthorhombic form of asenapine maleate, which through the use of a special crystallization technique, can be prepared in a highly pure form. 
Ovaj izum omogućuje ortorombski oblik asenapin maleata, koji se putem uporabe specijalne kristalizacijske tehnike, može dobiti u visoko čistom obliku.
the first fusion protein is SEQ ID NO:1 or an amino acid that is at least 95% identical to SEQ ID NO:1; and 
(a) prvi fuzijski protein je SEQ ID NO: 1 ili aminokiselina koja je najmanje 95% identična sa SEQ ID NO:1; 1
An aqueous pharmaceutical composition comprising insulin glargine in a concentration of 300 U/mL for use in a method of providing a peakless long acting basal insulin in the treatment of Type I and Type II Diabetes Mellitus. 
Vodeni farmaceutski pripravak sa pH između 3.4 1 4.6 koji sadrži inzulin glargin naznačen time da je za uporabu u postupku za osiguravanje dugodjelujućeg bazalnog inzulina bez vrhunca u liječenju dijabetes melitusa tipa I i tipa IL, pri čemu pripravak sadrži 270 - 330 U/mL inzulin glargina.
In another embodiment, decolourisation is achieved by adsorption of the colouring substances onto a reversed phase sorbent, particularly an alkyl-bonded silica or onto cation exchange resin. 
U još jednom ostvarenju, obezbojenje se postiže adsorpcijom obojenih tvari na sorbent na reverznoj fazi, naročito alkil-vezani silicij ili na kation-izmjenjivačku smolu.